CO-ANANDA-SCIENTIFIC
14.3.2023 12:05:44 CET | Business Wire | Press release
The University of Nebraska Medical Center (UNMC) and ANANDA Scientific Inc. today announced that the first patient has been enrolled in an FDA-approved clinical trial evaluating Nantheia™ ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure™ delivery technology, for Post-Traumatic Stress Disorder (PTSD). (Clinical Trials.gov Identifier NCT05269459)
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230314005182/en/
Pictured above is principal investigator Matthew Rizzo, MD, FAAN, FANA, and Ananda Scientific CEO Sohail Zaidi. (Photo: Business Wire)
The trial is being led by principal investigator Matthew Rizzo, MD, FAAN, FANA, the Reynolds Professor and Chair of the UNMC Department of Neurological Sciences, chief physician for neurological services at Nebraska Medicine, and chief physician for neurosciences clinical programs at Nebraska Medicine.
“We are very excited to have this important trial underway,” said Dr. Rizzo. “Our collaboration with ANANDA Scientific is allowing us to advance evidence-based research into new therapeutics for the large PTSD patient population.”
Dr. Rizzo’s research team includes Jennifer Merickel, PhD, Cognitive Neuroscientist and Assistant Professor in the UNMC Department of Neurological Sciences, and Brigette Soltis-Vaughan, an Advanced Practice Registered Nurse,Clinician and Researcher in the UNMC Department of Psychiatry and Instructor in the UNMC Department of Neurological Sciences.
“Enrolling the first patient in our second PTSD clinical trial is an important milestone for ANANDA’s clinical development program,” said Sohail R. Zaidi, ANANDA’s Chief Executive Officer. “We are very pleased to be partnering with the UNMC’s research team in evaluating our promising drugfor this very debilitating condition.”
This phase II double-blind, placebo-controlled, randomized clinical study is planning to enroll 180 participants to provide rigorous evaluation of the efficacy and safety of Nantheia™ ATL5.
ABOUT NANTHEIA™ ATL5
Nantheia™ ATL5 is an investigational drug that uses cannabidiol in ANANDA’s proprietary Liquid Structure delivery technology. Pre-clinical and initial clinical studies show that ANANDA’s Liquid Structure™ delivery technology (licensed from Lyotropic Delivery Systems (LDS) Ltd in Jerusalem, Israel) enhances the effectiveness and stability of cannabidiol. Nantheia™ ATL5 is an oral product with 100mg cannabidiol per softgel capsule.
ABOUT University of Nebraska Medical Center
As Nebraska’s only public academic health sciences center, UNMC is committed to the education of a 21st century health care workforce, to finding cures and treatments for devastating diseases, to providing the best care for patients and to serving the state and its communities through award-winning outreach. UNMC has six colleges, two institutes and a graduate studies program, serving more than 4,400 students in about 90 programs. Researchers at UNMC perform cutting-edge research in neurological sciences, oncology, infectious disease, and other key areas.
ABOUT ANANDA SCIENTIFIC
ANANDA is a leading research-focused biopharmaceutical company pioneering high-caliber clinical studies evaluating therapeutic indications such as PTSD, Radiculopathic Pain, Anxiety and Opioid Use Disorder (Mt. Sinai and UCLA). The company employs patented delivery technology to make cannabinoids and other plant derived compounds highly bioavailable, water soluble, and shelf-life stable and focuses on producing effective, premium quality pharmaceutical products. The company is expanding its research base through multiple sponsored research agreements with universities to diversify its clinical portfolio.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005182/en/
About Business Wire
DK
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Morinaga Milk Achieves Self-Affirmed GRAS Status for LAC-Living+™, Expanding U.S. Opportunities for Its Postbiotic Ingredient7.7.2026 04:00:00 CEST | Press release
Clinical evidence–backed postbiotic supports mood and well-being with formulation flexibility for diverse applications Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy and functional ingredient company, today announced that it has achieved self-affirmed GRAS (Generally Recognized As Safe) status in the United States for LAC-Living+™ (L. helveticus MCC1848), its proprietary postbiotic ingredient. This milestone expands the commercial availability of LAC-Living+ in the U.S. market and enables its use in dietary supplements, functional foods, and beverages, supporting the development of products designed to address growing consumer demand for health and well-being solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706806943/en/ Growing Interest in Postbiotics and Mental Well-Being Consumer interest in proactive health management has expanded significantly in recent years, alongside increasing aw
Access Advance Welcomes New Licensors to the Video Distribution Patent Pool7.7.2026 02:00:00 CEST | Press release
Access Advance LLC today announced that Sharp, M&K Holdings, Tagivan and 9 other patent owners who own substantial video codec patent portfolios that cover the core technologies behind video decoding, processing, and streaming media delivery, have joined the Video Distribution Patent Pool (VDP Pool) in the first half of 2026. "The addition of all of these new Licensors’ patent portfolios is a real win for both the VDP Pool and our many existing and future Licensees,” said Peter Moller, CEO of Access Advance. “These companies have broad and deep patent portfolios and further enhance the program’s market leading position in resolving the licensing issues around the use of modern video codecs across all the diverse business models of internet video streaming.” The following patent holders have joined the VDP Pool as Licensors in the first half of 2026: Digital Insights Inc. Hanbat National University Industry-Academic Cooperation Foundation Hanwha Vision Co., Ltd. Industry-Academy Coopera
Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 01:00:00 CEST | Press release
Expanded footprint advances the company’s global strategy in key growth region for healthcare and pharma brands Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Ka
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release
The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom